The 5th domestic Ruckus Pharma capecitabine tablet was approved for production and deemed to have been reviewed

On January 20, the official website of the State Food and Drug Administration showed that Nanjing Rucko Pharma’s Class 4 generic capecitabine tablets were approved for production and deemed to have been reviewed, making it the fifth domestically-produced company to be approved
.
According to data from Minet.
com, the terminal sales of this product in China's public medical institutions will exceed 3 billion yuan in 2020
.
Source: State Food and Drug Administration official website Capecitabine is an oral fluoropyrimidine carbamate antitumor drug developed by Roche for the treatment of colorectal cancer, breast cancer,
etc.
Including the original manufacturer, there are currently 6 domestic companies that have the production approval for capecitabine tablets
.
According to data from Minet.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) will exceed 3 billion yuan in 2020
.
Affected by centralized procurement, sales in the first half of 2021 fell by more than 50% year-on-year
.
In China's urban physical pharmacy terminals, it is predicted that the sales growth rate of capecitabine tablets in 2021 will exceed 100%
.
Sales of Oral Antineoplastic Drugs in Urban Physical Pharmacies in China (Unit: RMB 10,000) Source: Competition Landscape of Urban Physical Pharmacy Terminals in China Remaining in double digits, year-over-year growth is expected to exceed 20% in 2021
.
In 2020, China's urban physical pharmacy terminal oral anti-tumor drug TOP5 product source: minet.
com China's urban physical pharmacy terminal competition landscape From the perspective of product rankings, the total market share of China's urban physical pharmacy terminal oral anti-tumor drug TOP5 products in 2020 is close to 40%, of which Sales of AstraZeneca's osimertinib, Chia Tai Tianqing's anlotinib, and Hausen's almetinib have risen rapidly
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: Minet China's urban physical pharmacy terminal competition pattern database covers 297 cities and above nationwide physical pharmacies (excluding county and rural physical pharmacies).
Monitored enlarged version of the city's brick-and-mortar pharmacy database
.
The above sales are calculated based on the average retail price of the product in the terminal
.
The statistics are as of January 20.
If there are any omissions, please correct me!